Cancel
Blueprint Medicines
Blueprint Medicines Employees
13 people indexed:
-
qy69v7@v9k76xqg3k16a110jf.x9j Sign up to see email
-
Brittany Carroll
Vice President, Therapy Area Lead
1ky76160@jhzjwkvv9qy4h61g68.xxy Sign up to see email64vgyf2v@6j9vvx119h80h55gg0.9k7 Sign up to see email -
f5yqkx@j0aqwqvqaywhax8jvq.3zj Sign up to see email
-
Christopher Murray
Chief Technical Operations & Quality Officer
x92h8q7@xfg48wq7hf48hvf716.0f8 Sign up to see email1h2vxv8@7xh56j682vhq02g6ff.jf1 Sign up to see email -
Fouad Namouni
President, Research & Development
xy4h4181@h78xk03qqk75hy73j0.9k4 Sign up to see email7zw10765@yxh8v8kj9h4y4q75j8.98j Sign up to see email -
zqz@v2vxx8q9aa94av56zz.852 Sign up to see email
-
Jim Baker
Senior Vice President, Corporate Affairs
v6y63z@2v8158gf0qx0zv7632.41y Sign up to see emailhyywvh@2274y2304y186yz51y.gf4 Sign up to see email -
Kate Haviland
President and Chief Executive Officer
q749gq7q8@w30f3x1fg8q2x0gw92.yyw Sign up to see emailf6985664w@478fq2514wxxgy0qg2.82q Sign up to see email -
f05470j6714@v9k868q05gz25j593j.00q Sign up to see email
-
fw6y3jh@9x35zjxx1vkgw214w8.f80 Sign up to see email
-
q5a5@8z0jkj36zyzzh63kv7.v11 Sign up to see email
-
Sherwin Sattarzadeh
Senior Vice President, Strategic Operations & Chief of Staff
v25qj65xw491@346gy1998754g28j5x.4vw Sign up to see email9gw647fxw731@240yj8y83k5qf4xq90.716 Sign up to see email -
Tracey L. McCain
Executive Vice President, Chief Legal and Compliance Officer
k8.1vz1v5@k368jwq594q608fvq6.941 Sign up to see emailq4.wz480z@x2144x68y4zf25984z.037 Sign up to see email
Blueprint Medicines' Innovative Therapies
Blueprint Medicines specializes in developing and commercializing groundbreaking therapies that target the root causes of diseases. By focusing on the molecular and genetic underpinnings of diseases, the company aims to create highly effective treatments. This strategic approach has positioned Blueprint Medicines at the forefront of medical innovation, particularly in the fields of allergy/inflammation and oncology/hematology.
Blueprint Medicines' Approved Medicines
Blueprint Medicines has successfully commercialized AYVAKIT/AYVAKYT (avapritinib) in both the U.S. and Europe. This medication is a testament to the company's ability to translate scientific discoveries into viable therapies that can significantly improve patient outcomes. AYVAKIT/AYVAKYT is primarily used to treat specific types of gastrointestinal stromal tumors (GISTs) and systemic mastocytosis, underscoring the company's focus on addressing unmet medical needs.
Blueprint Medicines' Drug Discovery Approach
Employing a modality-agnostic drug discovery approach, Blueprint Medicines leverages a variety of technologies and methodologies to identify and develop new therapies. This flexible strategy allows the company to adapt and incorporate the latest scientific advancements, including targeted protein degradation and artificial intelligence (AI). This approach not only enhances their R&D capabilities but also accelerates the development of transformative medicines.
Blueprint Medicines' Collaborations and Licensing
Blueprint Medicines actively engages in strategic collaborations and licensing agreements to bolster its product portfolio. By partnering with other leading biotech and pharmaceutical companies, Blueprint Medicines can access additional resources and expertise, expanding its reach and accelerating the development of innovative therapies. These collaborations are crucial for maintaining the company's competitive edge in a rapidly evolving industry.
Blueprint Medicines' Patient Support Programs
Blueprint Medicines is committed to supporting patients through programs such as YourBlueprint in the U.S. This initiative provides patients with comprehensive support, including financial assistance, education, and personalized care plans. Additionally, the company offers early access programs for investigational therapies, ensuring that patients with urgent medical needs can benefit from the latest advancements in treatment.
Report inaccurate information
Report inaccurate information
